State coverage
Oregon
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Excludes these drugs from its Prioritized List of Health Services entirely, not from a drug list.
- Appeal deadline
- 60 days from the date on the notice, to your CCO or to OHA. 10 days from the effective date to keep a service running source
- Date read
- September 2026
Oregon ends up in the same place as several other states, but it gets there in a way that changes what you can do about it.
The Oregon Health Plan does not start by deciding drug by drug. It ranks health services on a Prioritized List, pays down to a cutoff, and covers what sits above it. Obesity has its own line, and the guideline attached to that line says what treating it means: intensive counseling on food and exercise. Not medication.
Then it says so plainly: drugs and devices for obesity are not meant to be on that line, or on any other line. Nothing on the list means nothing the plan buys. So the door closed a level above the drug list, which is why arguing about the drug list will not open it.
You can still get these drugs for something other than obesity, and Oregon says exactly where that line falls for each one. If you are under 21, the state reviews it case by case instead.
What we could verify for Oregon
Oregon settles what treating obesity means before it decides what to pay for. Guideline Note 5, attached to Line 317, states: "Medical treatment of overweight (with known cardiovascular risk factors) and obesity in adults is limited to intensive counseling on nutrition and physical activity, provided by health care professionals." It defines intensive counseling as "face-to-face contact more than monthly", includes it for six months, and allows a further six "as long as there is evidence of continued weight loss or improvement in cardiovascular risk factors based on the intervention."
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 · source
The same note keeps the drugs off the list entirely, rather than off a formulary: "Pharmacological treatments and devices (e.g., gastric balloons, duodenal jejunal bypass liners, and vagus nerve blocking devices) for obesity are not intended to be included as services on this line or any other line on the Prioritized List." That is a decision about which services the plan buys at all, taken one level above any drug list.
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 · source
That decision lives in the Prioritized List itself, which is dated on its face: the edition in force is headed "FEBRUARY 1, 2026" and footed "Including errata and revisions as of 8-13-2026".
Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services, effective February 2026 · source
The pharmacy criteria draw the line drug by drug, in a note rather than a table: "Semaglutide is not currently covered for adults who do not have established cardiovascular disease, metabolic dysfunction-associated steatohepatitis (MASH), or type 2 diabetes. Tirzepatide is not currently covered for adults who do not have established obstructive sleep apnea or type 2 diabetes. Liraglutide is not covered for adults who do not have type 2 diabetes or MASH." Authorization runs "Up to 6 months" with "Renewal up to 12 months".
Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 · source
Under 21, someone looks at your case instead of the list deciding it. Among the stated goals of the weight management criteria is to "Allow case-by-case review for members covered under the EPSDT program", alongside a goal to "Recommend use of GLP-1 receptor agonists only for FDA-approved indications supported by the evidence." The same section requires prior authorization for "All drugs used for weight management."
Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 · source
You get 60 days either way, counted from the date printed on your letter, not from when you opened it. For coordinated care members, "Your CCO must receive your appeal within 60 days from the date on the Notice of Adverse Benefit Determination." For a state denial the hearing form must reach the agency within "60 calendar days of the date on the Notice of Denial from OHA, or 120 calendar days of the date of the Notice of Appeal Resolution". Keeping a service running is a much shorter and differently anchored clock: ask "within 10 days of the effective date on the notice from the CCO or OHA."
Oregon Health Authority, Oregon Health Plan — Appeals and Hearings · source
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
- CoreAge RxAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
- OakFlat price across doses, free shipping with supplies.
- Care Bare RxNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
- Gala HealthAll doses one price, but the advertised rate needs a yearly subscription.
- Synergy RxProviders licensed in your state; publishes no GLP-1 price before the consult.
- Breeze MedsServes all 50 states; publishes a starting price only.
Prices in those notes were read from each company's own site in August 2026 and change often. Check the current number before you buy.
Where this comes from
- Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services — Guideline Notes, effective February 2026 — www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/2-1-2026GL.txt
- Oregon Health Authority, Health Evidence Review Commission, Prioritized List of Health Services, effective February 2026 — www.oregon.gov/oha/HPA/DSI-HERC/PrioritizedList/2-1-2026%20Prioritized%2
- Oregon Health Authority, Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria Guide, effective July 2026 — www.oregon.gov/oha/HSD/OHP/Tools/Oregon%20Medicaid%20PA%20Criteria%20Gui
- Oregon Health Authority, Oregon Health Plan — Appeals and Hearings — www.oregon.gov/oha/HSD/OHP/Pages/Appeals-Hearings.aspx
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.